Terns Pharmaceuticals (430) Stock Overview

A clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. More details

430 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Analysts in good agreement that stock price will rise by 58.8%

Risk Analysis

Earnings are forecast to decline by an average of 2.8% per year for the next 3 years

Makes less than USD$1m in revenue ($0)

Highly volatile share price over the past 3 months compared to the German market

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 more risk

430 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Terns Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Terns Pharmaceuticals
Historical stock prices
Current Share Price	US$30.80
52 Week High	US$39.80
52 Week Low	US$1.70
Beta	-0.28
1 Month Change	-8.33%
3 Month Change	340.00%
1 Year Change	465.14%
3 Year Change	305.26%
5 Year Change	n/a
Change since IPO	114.63%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	430	DE Pharmaceuticals	DE Market
7D	6.2%	-1.4%	-0.4%
1Y	465.1%	17.2%	13.2%

Return vs Industry: 430 exceeded the German Pharmaceuticals industry which returned 17.2% over the past year.

Return vs Market: 430 exceeded the German Market which returned 13.2% over the past year.

Price Volatility

Is 430's price volatile compared to industry and market?
430 volatility
430 Average Weekly Movement	25.3%
Pharmaceuticals Industry Average Movement	7.7%
Market Average Movement	5.2%
10% most volatile stocks in DE Market	12.3%
10% least volatile stocks in DE Market	2.5%

Stable Share Price: 430's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 430's weekly volatility has increased from 16% to 25% over the past year.

About the Company

Founded	Employees	CEO	Website
2016	59	Amy Burroughs	www.ternspharma.com

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.

Terns Pharmaceuticals, Inc. Fundamentals Summary

How do Terns Pharmaceuticals's earnings and revenue compare to its market cap?
430 fundamental statistics
Market cap	€3.42b
Earnings (TTM)	-€81.10m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-42.2x

P/E Ratio

Is 430 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
430 income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$94.44m
Earnings	-US$94.43m

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-0.87
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 430 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/01/19 00:40
End of Day Share Price	2026/01/19 00:00
Earnings	2025/09/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Terns Pharmaceuticals, Inc. is covered by 17 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Etzer Darout	Barclays
Etzer Darout	BMO Capital Markets Equity Research
Evan Seigerman	BMO Capital Markets Equity Research